# Liver Regeneration and Carcinogenesis

Molecular and Cellular Mechanisms

Edited by Randy L. Jirtle

**Academic Press** 

# Liver Regeneration and Carcinogenesis Molecular and Cellular Mechanisms

Edited by Randy L. Jirtle

Department of Radiation Oncology Duke University Medical Center Durham, North Carolina



Academic Press

San Diego New York Boston London Sydney Tokyo Toronto

Cover illustration: A Modification of Figure 1 from Chapter 4 of this volume.

This book is printed on acid-free paper.

Copyright © 1995 by ACADEMIC PRESS, INC.

All Rights Reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

Academic Press, Inc.

A Division of Harcourt Brace & Company 525 B Street, Suite 1900, San Diego, California 92101-4495

United Kingdom Edition published by Academic Press Limited 24-28 Oval Road, London NW1 7DX

Library of Congress Cataloging-in-Publication Data

Liver regeneration and carcinogenesis: molecular and cellular mechanisms / edited by Randy L. Jirtle.

p. cm.

Includes index.

ISBN 0-12-385355-9 (case : alk. paper)

1. Liver--Cancer. 2. Liver--Regeneration. 3. Pathology,

Molecular. 4. Liver--Molecular aspects. I. Jirtle, Randy L.

[DNLM: 1. Liver Regeneration. 2. Liver Neoplasms--genetics WI 702 L7848 1995]

RC280.L5L587 1995

6516.3'62--dc20

DNLM/DLC

for Library of Congress

95-14344

CIP

PRINTED IN THE UNITED STATES OF AMERICA

95 96 97 98 99 00 QW 9 8 7 6 5 4 3 2 1

## Liver Regeneration and Carcinogenesis Molecular and Cellular Mechanisms

This book is dedicated to my wife Nancy and my children, Bonnie and James.

## Contributors

Numbers in parentheses indicate the pages on which the authors' contributions begin.

- R. Daniel Beauchamp (323) Department of Surgery, Vanderbilt University, Nashville, Tennessee 77550
- Ivan J. Boyer (199) MITRE Corporation, Inc., McLean, Virginia 22102
- Silvana Breiteneder-Geleff (113) Institute of Clinical Pathology, University of Vienna Medical School, A-1090 Vienna, Austria
- Nancy L. R. Bucher (1) Department of Pathology, Boston University School of Medicine, Boston, Massachusetts 02118
- Wilfried Bursch (141) Institute für Tumor Biologie-Cancer Research, A-1090 Wien, Austria
- Laura L. Byrd (179) Department of Pathology, and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599
- Ravi S. Chari (323) Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710
- Chia Chiao (179) Department of Pathology, and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599
- Paolo M. Comoglio (51) Institute for Cancer Research and Treatment (IRCC), University of Torino School of Medicine, 10126 Torino, Italy
- Jennifer L. Counts (227) Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan 48824
- Norman R. Drinkwater (301) McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, Madison, Wisconsin 53076
- Shih Gong (113) Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, New York 10461
- Jay I. Goodman (227) Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan 48824

xviii Contributors

Bettina Grasl-Kraupp (141) Institute für Tumor Biologie-Cancer Research, A-1090 Wien, Austria

- Brian E. Huber (351) Wellcome Research Laboratories, Research Triangle Park, North Carolina 27709
- Randy L. Jirtle (199) Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710
- David G. Kaufman (179) Department of Pathology, and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599
- William K. Kaufmann (179) Department of Pathology, and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599
- Gang-Hong Lee (301) Department of Pathology, Asahikawa Medical College, Asahikawa 078, Japan
- **George K. Michalopoulos** (27) Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15261
- Jeremy J. Mills (199) Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710
- Charles E. Rogler (113) Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, New York 10461
- Leslie E. Rogler (113) Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, New York 10461
- Eric P. Sandgren (257) Department of Experimental Pathology, School of Veterinary Medicine, University of Wisconsin–Madison, Madison, Wisconsin 53706
- Rolf Schulte-Hermann (141) Institute für Tumor Biologie-Cancer Research, A-1090 Wien, Austria
- Rebecca Taub (71) Department of Genetics and Medicine, Howard Hughes Medical Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
- Snorri S. Thorgeirsson (99) Laboratory of Experimental Carcinogenesis, Division of Cancer Etiology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
- Elisa Vigna (51) Institute for Cancer Research and Treatment (IRCC), University of Torino School of Medicine, 10126 Torino, Italy
- Haiping Wang (113) Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, New York 10461

Contributors

Deyun Yang (113) Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, New York 10461

Yingchun Zhang (179) Department of Pathology, and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599

## **Preface**

The fact that the liver regenerates following injury has been known since ancient times. According to Greek mythology, Prometheus was chained to a rock for defying Zeus by stealing fire from Mount Olympus. He was subjected to an eagle eating his liver during the day, and it regenerated by night. Because of this marked capacity to regenerate and the ability of chemical carcinogens and viruses to transform hepatocytes, the liver is used extensively as a model for investigating the molecular mechanisms of normal cell proliferation and carcinogenesis.

Recently, striking advances have occurred in our understanding of hepatocyte growth regulation and how chemical agents and viruses alter these normal growth regulatory pathways during the genesis of liver tumors. Both *in vitro* and *in vivo* models of neoplastic transformation have established that the pathway to neoplasia has multiple steps. Aberrant expression of proto-oncogenes or the expression of mutant forms of these genes (i.e., oncogenes) can lead to neoplastic transformation. The loss of tumor suppressor gene function is also involved in the development of both rodent and human liver cancer. This book demonstrates that the determination of the factors involved in controlling the regeneration of normal liver has led to a clearer understanding of the mechanisms involved in the formation of various liver diseases, including hepatocellular carcinomas.

The chapters in this book are grouped into three main research areas. The first section of the book covers the subject of liver regeneration. Liver regeneration has been investigated for many years, particularly since 1931 when Higgins and Anderson published a classic paper describing a partial hepatectomy technique in rats that reproducibly stimulates the liver to regeneration. An overview of liver regeneration research both then and now is described in the first chapter by one of the premier scientists in this field of investigation, Dr. Nancy Bucher. The growth factor that plays a central role in stimulating hepatocyte proliferation following liver injury, hepatocyte growth factor, and its receptor (c-met) are discussed in Chapters 2 and 3, respectively. The immediate-early response genes that are expressed in the early stages of liver regeneration are described in Chapter 4.

The second section of this book deals with the subject of liver carcinogenesis. The topics were chosen to provide an overview of this immense subject.

xxii Preface

Chapter 5 covers the role that hepatic stem cells play in both liver regeneration and carcinogenesis. It is well known that hepatitis virus infection is a major risk factor for the development of human hepatocellular carcinomas. The contribution of hepadnavirus research to our understanding of liver cancer is discussed in Chapter 6. Programmed cell death, apoptosis, has been increasingly shown to be mechanistically involved in liver tumor promotion and carcinogenesis as discussed in Chapter 7. Transforming growth factor β and the suppression of p53-dependent cell cycle checkpoint function as they relate to liver tumor promotion are discussed in Chapters 8 and 9. In Chapter 10 it is postulated that hypomethylation of the DNA may represent an epigenetic mechanism for hepatocyte transformation. The use of transgenic animals to ascertain directly the role of growth factors, oncogenes, etc., in liver carcinogenesis is a powerful molecular technique thoroughly presented in Chapter 11. It is also important to realize that humans vary in their susceptibility to tumor formation. Chapter 12 describes the importance of genetics in the development of liver tumors in both humans and animals.

The final section of this book deals with two vastly different techniques for treating liver cancer. Although hepatocellular carcinoma is one of the most common neoplasms in the world, primary cancer of the liver is relatively rare in the United States. Hepatocellular carcinomas are, however, still of significance in the United States because they are highly lethal; the 5-year survival rate is less than 10%. One method of treating primary and metastatic liver tumors is surgical resection. When the malignancy is not amenable to a simple resection, the whole liver can now be transplanted. These surgical procedures for the treatment of liver cancer are described in Chapter 13. As the genes involved in liver carcinogenesis are elucidated, it becomes more probable that this information will be used to develop successful molecular strategies for cancer treatment. The potential of using gene therapy approaches to treat liver tumors and genetic liver diseases is discussed in Chapter 14.

In conclusion, the veritable explosion of scientific information that has occurred recently in liver biology encompasses many research disciplines. This book is an attempt to bring these diverse research results together in a coherent manner. Scientists who will benefit from this book include toxicologists, virologists, molecular biologists, cell biologists, cancer biologists, pharmacologists, pathologists, surgeons, and gastroenterologists who are interested in furthering their understanding of the molecular mechanisms controlling liver regeneration and hepatocellular carcinogenesis.

I would like to thank Ms. Charlotte Brabants at Academic Press for her continued support and patience, the contributors of this book for writing their chapters when it is increasingly difficult to find the time for such Preface xxiii

scholarly endeavors, and Ms. Roxanne Scroggs for her secretarial assistance.

Randy L. Jirtle

此为试读,需要完整PDF请访问: www.ertongbook.com

## Contents

Contributors xvii

xxi

Preface

| 1   |
|---|
| Liver Regeneration Then and Now   |
| Nancy L. R. Bucher  |
| <ul> <li>I. Landmarks 1</li> <li>II. Normal Adult Rat Liver 2</li> <li>III. Liver Regeneration 3</li> <li>IV. Hepatocyte Priming 5</li> <li>V. Regeneration Signals 7  A. Hormones 7  B. Growth Factors 12  C. Cytokines 17  D. Interactions 18</li> <li>VI. Conclusions 19  References 19</li> </ul> |
| 2 Hepatocyte Growth Factor (HGF) and Its Receptor (Met) in Liver Regeneration, Neoplasia and Disease George K. Michalopoulos  |
| I. Introduction 27 II. Structural and Functional Aspects of HGF and the HGF Receptor 28 III. HGF Localization 30 A. In Liver 30   |

B. In Extra Hepatic Tissues

31

Contents viii

| IV. Liver and the Processing of HGF 32            |  |
|---|--|
| A. HGF and Liver Regeneration 33                  |  |
| V. HGF and the Early Proteolytic Events Following |  |
| Partial Hepatectomy 37                            |  |
| VI. HGF Localization 40                           |  |
| A. In Liver Embryogenesis 40                      |  |
| B. In Liver Disease 41                            |  |
| C. In Liver Carcinogenesis 42                     |  |
| VII. Summary 43                                   |  |
| References 44                                     |  |
|   |  |
| 3   |  |
| Structure and Functions of the HGF                |  |
| Receptor (c-Met)                                  |  |
| <u> </u>  |  |
| Paolo M. Comoglio                                 |  |
| Elisa Vigna                                       |  |
| I. Hepatocyte Growth Factor and                   |  |
| Scatter Factor 51                                 |  |
| II. HGF Receptor 53                               |  |
| A. Encoding by the c-met Oncogene 53              |  |
| B. Post-translational Modifications 54            |  |
| C. Positive and Negative Regulation 55            |  |
| D. Signal Transduction 57                         |  |
| E. Tissue Distribution and Subcellular            |  |
| Localization 59                                   |  |
| III. Regulation of c-met Expression 60            |  |
| IV. Role of HGF in Tissue Regeneration            |  |
| and Embryogenesis 61                              |  |
| V. Role of c-met in Carcinogenesis 62             |  |
| References 63                                     |  |
|   |  |
| 4   |  |
| Expression and Function of Growth-Induced         |  |
| Genes during Liver Regeneration                   |  |
| Rebecca Taub                                      |  |
| Redecca Taud                                      |  |
| I. Liver Regeneration:                            |  |
| The Important Questions 71                        |  |
| II. Immediate-Early Gene Expression               |  |

in Hepatic Cells

72 III. Modification of Preexisting Transcription Factors

| Contents                 |  |
|--------------------------|--|
| ***                      | Immediately Following Partial Hepatectomy Turns on Immediate-Early Genes 76  |
| IV.                      | Induction Patterns of 70 Genes Following Partial<br>Hepatectomy Define the Temporal Course<br>of Liver Regeneration 78 |
| V.                       | Transcription Factors Induced in the   |
|                          | Regenerating Liver 80  |
|                          | A. The LRF-1/JunB Story 80   |
|                          | B. RNR-1, a Novel Nuclear Receptor That Acts   |
|                          | through the NGFI-B Half-Site 82  |
| VI.                      | Immediate-Early Genes Involved in Signal   |
|                          | Transduction 84  |
|                          | A. PRL-1, a Member of a Novel Class of   |
|                          | Protein-Tyrosine Phosphatases 84   |
| VII.                     | Immediate-Early Genes That Are   |
| 17111                    | Secreted Proteins 86   |
| VIII.                    | Liver-Specific Immediate-Early Genes:  |
|                          | Relationship to the Maintenance of Hepatocyte Differentiation and Metabolism 87  |
|                          | A. Identification of CL-6 88   |
| IX                       | Immediate-Early Genes in H35 Cells That Are  |
| 121.                     | Expressed as Delayed-Early Genes   |
|                          | in Regenerating Liver 89   |
|                          | A. Delayed-Early Genes That Encode RNA   |
|                          | Binding Proteins 89  |
| X.                       | Conclusions 91   |
|                          | References 93  |
| 5                        |  |
| Stem Co<br>Snorri S. Tho | ells and Hepatocarcinogenesis  |
| I.                       | Introduction 99  |
|                          | Cellular Biology of the Hepatic Stem Cell  |
|                          | Compartment 101  |
|                          | A Experimental Systems in Vivo 101   |

B. Experimental Systems in Vitro 102

III. Neoplastic Development in the Liver 104

A. Hepatic Stem Cells and Hepatocarcinogenesis 104

B. Transformation of Liver Derived Epithelial (Oval) Cells 106

IV. Conclusions 108 References 109

X Contents

6

# Contributions of Hepadnavirus Research to Our Understanding of Hepatocarcinogenesis

Charles E. Rogler Leslie E. Rogler Deyun Yang Silvana Breiteneder-Geleef Shih Gong Haiping Wang

- I. General Overview of Hepadnavirus Animal Models and Hepatocarcinogenesis 113
- II. Hepatitis B Virus Envelope Protein (HBsAg) Transgenic Mice 117
  - A. HBsAg (Line 50-4) Transgenic Model of Hepatocarcinogenesis 117
  - B. Noncytopathic HBsAg Transgenic Mice: Role of Cytokines in Gene Regulation 118
- III. Woodchuck Hepatitis Virus (WHV) Model of Hepatocarcinogenesis 122
  - A. Toxic Oxygen Radicals and WHV Persistent Infection 122
  - B. Insertional Mutagenesis 122
  - C. Integration and Human HCC 125
  - D. Analysis of Precancerous Lesions and HCCs:
    The Case for a Role of IGF2 in Tumor Promotion 125
- IV. Hepadnavirus X Gene Encodes an Oncogenic

Transcriptional Transactivator 1

- A. Background 129
- B. X Gene Transactivation Mechanism 131
- C. *In Vitro* Assays for Hepadnavirus Transforming Activity 132
- D. HBx Transgenic Mice Develop HCC 132
- V. Conclusions 134 References 134

7

### Apoptosis and Hepatocarcinogenesis

Rolf Schulte-Hermann Bettina Grasl-Kraupp Wilfried Bursch

> I. Apoptosis and Other Types of Active Cell Death 141

|  | C. Duration of Apoptosis in the Liver 151  |
|--|--|
| III.   | Biochemical and Molecular Aspects  |
|  | of Apoptosis 152   |
|  | A. Events Associated with Cell Killing 153   |
|  | B. Events Associated with Preparation for Active   |
|  | Cell Death 154   |
|  | C. Signal Factors 156  |
| IV.  | Active Cell Death in the Stages of   |
|  | Hepatocarcinogenesis 158   |
|  | A. Cancer Prestages in the Liver 158   |
|  | B. Kinetic Aspects of Cell Proliferation and Death   |
|  | in Cancer Prestages 160  |
|  | C. Active Cell Death and Initiation 161  |
|  | D. Active Cell Death and   |
|  | Tumor Promotion 163  |
|  | E. Active Cell Death and Tumors 165  |
| V  | Conclusions 166  |
| ٧.   | References 167   |
|  | References 107   |
|  |  |
|  |  |
| 8  |  |
|  | Sympa Dromotion and the Sympassica of  |
| Liver T  | Sumor Promotion and the Suppression of   |
| Liver T  | Fumor Promotion and the Suppression of ependent Cell Cycle Checkpoint Function   |
| Liver T  | pendent Cell Cycle Checkpoint Function   |
| Liver T  | pendent Cell Cycle Checkpoint Function   |
| Liver T<br>p53-De<br>Yingchun Z  | ependent Cell Cycle Checkpoint Function  |
| Liver T<br>p53-De<br>Yingchun Zi<br>Chia Chiao   | ependent Cell Cycle Checkpoint Function  hang  |
| Liver T<br>p53-De<br>Yingchun Z<br>Chia Chiao<br>Laura L. By   | ependent Cell Cycle Checkpoint Function  hang  rd  nufman  |
| Liver T<br>p53-De<br>Yingchun Z<br>Chia Chiao<br>Laura L. By<br>David G. Ka<br>William K. I                | ependent Cell Cycle Checkpoint Function thang rd nufman Kaufmann   |
| Liver T<br>p53-De<br>Yingchun Z<br>Chia Chiao<br>Laura L. By<br>David G. Ka<br>William K. I                | ependent Cell Cycle Checkpoint Function hang rd nufman Kaufmann Introduction 179   |
| Liver T<br>p53-De<br>Yingchun Z<br>Chia Chiao<br>Laura L. By<br>David G. Ka<br>William K. I<br>I.          | ependent Cell Cycle Checkpoint Function hang  rd nufman Kaufmann Introduction 179 Mechanisms of Cell Cycle Control 180   |
| Liver T<br>p53-De<br>Yingchun Z<br>Chia Chiao<br>Laura L. By<br>David G. Ka<br>William K. I<br>I.          | ependent Cell Cycle Checkpoint Function hang  rd hufman Kaufmann  Introduction 179 Mechanisms of Cell Cycle Control 180 Cell Cycle Checkpoints, Lifespan Extension,  |
| Liver T<br>p53-De<br>Yingchun Z<br>Chia Chiao<br>Laura L. By<br>David G. Ka<br>William K. I<br>II.<br>III. | ependent Cell Cycle Checkpoint Function hang  rd hang  Raufmann  Introduction 179  Mechanisms of Cell Cycle Control 180  Cell Cycle Checkpoints, Lifespan Extension, and Genetic Instability 181   |
| Liver T<br>p53-De<br>Yingchun Z<br>Chia Chiao<br>Laura L. By<br>David G. Ka<br>William K. I<br>II.<br>III. | ependent Cell Cycle Checkpoint Function thang  rd that the summan that the sum |
| Liver T<br>p53-De<br>Yingchun Z<br>Chia Chiao<br>Laura L. By<br>David G. Ka<br>William K. I<br>II.<br>III. | rd nufman Kaufmann Introduction 179 Mechanisms of Cell Cycle Control 180 Cell Cycle Checkpoints, Lifespan Extension, and Genetic Instability 181 Isolation of EL/EGV Hepatocytes and Promotion of Hepatocarcinogenesis in Vitro 183  |
| Liver T<br>p53-De<br>Yingchun Z<br>Chia Chiao<br>Laura L. By<br>David G. Ka<br>William K. I<br>II.<br>III. | rd nufman Kaufmann Introduction 179 Mechanisms of Cell Cycle Control 180 Cell Cycle Checkpoints, Lifespan Extension, and Genetic Instability 181 Isolation of EL/EGV Hepatocytes and Promotion of Hepatocarcinogenesis in Vitro 183 Immortal Rat Hepatocytes Require PB  |
| Liver Tp53-De Yingchun Z Chia Chiao Laura L. By David G. Ka William K. I II. III. IV. V.                   | rd sufman Kaufmann Introduction 179 Mechanisms of Cell Cycle Control 180 Cell Cycle Checkpoints, Lifespan Extension, and Genetic Instability 181 Isolation of EL/EGV Hepatocytes and Promotion of Hepatocarcinogenesis in Vitro 183 Immortal Rat Hepatocytes Require PB for Clonal Expansion 186   |
| Liver Tp53-De Yingchun Z Chia Chiao Laura L. By David G. Ka William K. I II. III. IV. V.                   | ependent Cell Cycle Checkpoint Function hang  rd hufman Kaufmann  Introduction 179 Mechanisms of Cell Cycle Control 180 Cell Cycle Checkpoints, Lifespan Extension, and Genetic Instability 181 Isolation of EL/EGV Hepatocytes and Promotion of Hepatocarcinogenesis in Vitro 183 Immortal Rat Hepatocytes Require PB for Clonal Expansion 186 Mechanisms of Promotion of   |
| Liver Tp53-De Yingchun Z Chia Chiao Laura L. By David G. Ka William K. I II. III. IV. V. VI.               | rd sufman  Kaufmann  Introduction 179 Mechanisms of Cell Cycle Control 180 Cell Cycle Checkpoints, Lifespan Extension, and Genetic Instability 181 Isolation of EL/EGV Hepatocytes and Promotion of Hepatocarcinogenesis in Vitro 183 Immortal Rat Hepatocytes Require PB for Clonal Expansion 186 Mechanisms of Promotion of Hepatocarcinogenesis by Phenobarbital 191  |
| Liver Tp53-De Yingchun Z Chia Chiao Laura L. By David G. Ka William K. I II. III. IV. V. VI.               | ependent Cell Cycle Checkpoint Function hang  rd hufman Kaufmann  Introduction 179 Mechanisms of Cell Cycle Control 180 Cell Cycle Checkpoints, Lifespan Extension, and Genetic Instability 181 Isolation of EL/EGV Hepatocytes and Promotion of Hepatocarcinogenesis in Vitro 183 Immortal Rat Hepatocytes Require PB for Clonal Expansion 186 Mechanisms of Promotion of   |

II. Active Cell Death in the Liver 145 A. Detection and Quantification 145

146

B. Models

9

#### Mechanisms of Liver Tumor Promotion

Jeremy J. Mills Randy L. Jirtle Ivan J. Boyer

- I. Introduction 199
- II. Stages of Liver Carcinogenesis 201
  - A. Initiation 201
  - B. Promotion 202
  - C. Progression 203
- III. Cell Cycle Regulation and Liver

Carcinogenesis 204

- A. Cyclins and Cyclin-Dependent Kinases 205
- B. Rb Gene 206
- C. p53 Gene 207
- IV. TGFβ and Liver Carcinogenesis 208
  - A. TGFβ and TGFβ Receptors 210
  - B. M6P/IGF2 Receptor 212
  - C. Experimental Results 214
- V. Apoptosis and Liver Carcinogenesis 216
- VI. Summary 217 References 218

10

#### Hypomethylation of DNA: An Epigenetic Mechanism That Can Facilitate the Aberrant Oncogene Expression Involved in Liver Carcinogenesis

Jennifer L. Counts Jay I. Goodman

- I. Introduction 227
- II. Epigenetics 230
- III. DNA Methylation 230
- IV. Working Hypothesis and Experimental Model 235
- V. Liver Tumor Promotion: A Role for Hypomethylation of DNA 236
- VI. Methyl Deficient Diets 238
- VII. DNA Damage and Altered DNA Methylation 240